Title |
-
en
Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC astereotactic radiotherapy
|
Creator |
|
Accessrights |
metadata only access |
Rights |
|
Subject |
-
Other
en
Non-small cell lung cancer
-
Other
en
Hypoxia
-
Other
en
Fluoromisonidazole
-
Other
en
Fluorodeoxyglucose
-
Other
en
Stereotactic body radiation therapy
-
NDC
490
|
Description |
-
Abstract
en
Background: We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT). Patients and methods: We prospectively examined patients with pathologically proven NSCLC; all underwent FDG and FMISO PET/CT scans before SBRT. PET images were acquired using a whole-body time-of-flight PET-CT scanner with respiratory gating. We classified them into recurrent and non-recurrent groups based on their clinical followups and compared the groups' tumor diameters and PET parameters (i.e., maximum of the standardized uptake value (SUVmax), metabolic tumor volume, tumor-to-muscle ratio, and tumor-to-blood ratio). We performed univariate analysis to evaluate the impact of the PET variables on the patients' progression-free survival (PFS). We divided the patients by thresholds of FDG SUVmax and FMISO SUVmax obtained from receiver operating characteristic analysis for assessment of recurrence rate and PFS. Results: Thirty-two NSCLC patients (19 male and 13 females; median age, 83 years) were enrolled. All received SBRT. At the study endpoint, 23 patients (71.9%) were non-recurrent and nine patients (28.1%) had recurrent disease. Significant between-group differences were observed in tumor diameter and all the PET parameters, demonstrating that those were significant predictors of the recurrence in all patients. In the 22 patients with tumors > 2 cm, tumor diameter and FDG SUVmax were not significant predictors. Thirty-two patients were divided into three patterns from the thresholds of FDG SUVmax (6.81) and FMISO SUVmax (1.89); A, low FDG and low FMISO (n = 14); B, high FDG and low FMISO (n = 8); C, high FDG and high FMISO (n = 10). No pattern A patient experienced tumor recurrence, whereas two pattern B patients (25%) and seven pattern C patients (70%) exhibited recurrence. A Kaplan-Meier analysis of all patients revealed a significant difference in PFS between patterns A and B (p = 0.013) and between patterns A and C (p < 0.001). In the tumors > 2 cm patients, significant differences in PFS were demonstrated between pattern A and C patients (p = 0.002). Conclusion: The combination of FDG- and FMISO-PET can identify patients with a baseline risk of recurrence and indicate whether additional therapy might be performed to improve survival.
|
Publisher |
en
Springer (SpringerOpen)
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
NA |
Identifier |
HDL
http://hdl.handle.net/2115/77033
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.1186/s13550-019-0578-6
|
Journal |
-
-
en
EJNMMI research
-
Volume Number9
Issue Number1
Page Start104
|
Oaidate |
2023-07-26 |